P53 auto-antibodies in the sera of patients with oral squamous cell carcinoma

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 3183-3184

  Friedrich, R E ^a   Bartel Friedrich, S ^b   Plambeck, K ^a   Bahlo, M ^c   Klapdor, R ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c Ctr Clin Exp Tum Markers D   (Germany)

Author keywords

Oral squamous cell carcinoma; p53 auto antibodies; Serum

Indexed keywords

AUTOANTIBODY; PROTEIN P53; PROTEIN P53 AUTOANTIBODY; UNCLASSIFIED DRUG;

CANCER STAGING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; MOUTH CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

AUTOANTIBODIES; CARCINOMA, SQUAMOUS CELL; HUMANS; MOUTH NEOPLASMS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030864564     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, Armand JP, Riou G: High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases: absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10: 1217-1227, 1995
2. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, Goodman SN, Sidransky D:Molecular assessment of histo-pathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332: 429-435, 1995.
3. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch J, Forastiere A, Sidransky D: Association of cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. New Engl J Med 332: 712-717 1, 1995.
4. Burns JE, Baird MC, Clark LJ et al: Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines. Br J Cancer 67: 1274-1284, 1993.
5. Caron de Fromentel C, Soussi T: TP53 Tumour suppressor gene - a model for investigating human mutagenesis. Genes, Chromosomes and Cancer 4: 1-15, 1992
6. Chang YS, Lin YJ, Tsai CN, Shu CH, Tsai MS, Choo KB, Liu ST: Detection of mutations in the p53 gene in human head and neck carcinomas by single strand conformation polymorphism analysis. Cancer Letters 67: 167-174, 1992.
7. Dolcetti R, Doglioni C, Maestro R, et al: P53 overexpression is an early event in the development of human squamous cell carcinoma of the larynx: genetic and prognostic implications. Int J Cancer 52: 178-182, 1992.
8. Field JK: Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. Oral Oncol, Eur J Cancer 28B: 67-76, 1992.
9. Frank JL, Bur ME, Garb JL, Kay S, Ware JL, Sismanis A, Neifeld JP: p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 73: 181-186, 1994.
10. Fritzsche M, Haessler C, Brandner G: Induction of nuclear accumulation of the tumour suppressor protein p53 by DNA-damaeing agents. Oncogene 8: 807-818, 1993.
11. Gath HJ, Heissler E, Hell B, Bier J, Riethmuller G, Pautel K: Immunocytologic detection of isolated tumor cells in bone marrow of patients with squamous cell carcinomas of the head and neck region. Int J Oral Maxillofac Surg 24: 351-355, 1995.
12. Girod SC, Fischer U, Knüfermann R, Kramer Ch, Krüger GRF : p53-Mutationen bei Leukoplakien, Lichen planus und Karzinomen der Mundschleimhaut. Dtsch Z Mund Kiefer GesichtsChir 18: 250-253, 1994.
13. Gusterson BA, Anbazhagan R, Warren W et al: Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 6: 1785-1789, 1991.
14. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
15. Kastan MB, Zhan Q, El-Deiry WS et al: A mammalian cell cycle checkpoint pathway utilizing p53 and GAD45 is defective in ataxia telangiectasia. Cell 71: 587-597, 1992.
16. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7498, 1992.
17. Laregey JS, Meltzer SJ, Yin J, Norris K, Sauk JJ, Archibald DW: Loss of heterozygosity of p53 oral cancers demonstrated by the polymerase chain reaction. Cancer 71: 1933-1937, 1993.
18. Nylander K, Nilsson P, Mehle C, Roos G: p53 mutations, protein expression and cell proliferation in squamous cell carcinoma of the head and neck. Br J Cancer 71: 826-830, 1995.
19. Regezi JA, Zarbo RJ, Regev, Pisanty S, Siverman S, Gazit D. p53 protein expression in sequential biopsies of oral dysplasias and in situ carcinomas. J Oral Pathol Med 24: 18-22, 1995.
20. Volkmann M, Muller M, Hofmann WJ, Meyer M, Hagelstein J, Rath U, Kommerell B, Zentgraf H, Galle PR: The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status. Hepatalogy 18: 559-565, 1993.
21. Dr, Hansen, Dianova, Hamburg, personal communication (January 1996)